Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2552W HIGH $7.74
Volume
15.85 K
Value Traded
151.01 K
Short % Float
3.06%
-9.02%Week
+792.77%1 Month
+391.42%3 Month
+411.43%6 Month
-81.98%5 Year
-81.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.79 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
28.94 M
Total Shares
1.90 M
Float Shares
1.25 M
Insiders
34.02%
Institutions
1.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NRSN Catalyst Timeline
Dated clinical, regulatory and corporate events for NeuroSense Therapeutics Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NeuroSense Therapeutics Ltd.
436Total events
6Upcoming
93Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
NeuroSense to participate in 5th Annual ROTH Healthcare Opportunities Conference
◆Oral PresentationPresentation
NeuroSense to participate in Roth-hosted KOL webinar on ALS treatment
ALSsource ↗
▲Trial InitiationPrimeCTrial
FDA clearance to initiate pivotal Phase 3 PARAGON trial of PrimeC in ALS
ALSsource ↗
●Quarterly UpdateCorporate
Reported H1 2026 financial results with R&D expenses of $2,102 thousand and G&A of $1,345 thousand
◆Oral PresentationPrimeCPresentation
EverythingALS community event discussing emerging data on PrimeC
ALSsource ↗
▲Patent GrantedPrimeCIP / Competition
South Korean patent granted covering PrimeC composition for ALS
amyotrophic lateral sclerosis (ALS)source ↗
▲Patent GrantedPrimeCIP / Competition
Japanese Patent 7857044 granted for PrimeC composition and formulation
amyotrophic lateral sclerosis (ALS)source ↗
◆Timing GuidancePrimeCPresentation
Potential NDS submission to Health Canada
amyotrophic lateral sclerosis (ALS)source ↗
▲Primary Endpoint MetPrimeCClinical Data
PARADIGM achieved primary endpoint with statistically significant reduction in EV-associated TDP-43 vs placebo
amyotrophic lateral sclerosis (ALS)source ↗
◆Pre NDA MeetingPrimeCFDA Meeting
Pre-NDS meeting with Health Canada rescheduled to May 2026
ALSsource ↗
▲Patent GrantedPrimeCIP / Competition
Brazilian patent granted covering PrimeC composition
ALS, Alzheimer's diseasesource ↗
▼Quarterly UpdateCorporate
Received Nasdaq notification for minimum market value of listed securities non-compliance
◆Topline ReadoutPrimeCClinical Data
Clinical and biomarker results from Alzheimer's study expected in coming weeks
Alzheimer's diseasesource ↗
◆Pre NDA MeetingPrimeCFDA Meeting
Pre-NDS meeting with Health Canada
amyotrophic lateral sclerosis (ALS)source ↗
◆Oral PresentationPrimeCPresentation
Presentation of PARADIGM Phase 2b clinical and biomarker insights at AD/PD 2026
amyotrophic lateral sclerosis (ALS)source ↗
▲PublicationPrimeCPresentation
JAMA Neurology publishes results from PARADIGM Phase 2b trial of PrimeC in ALS
amyotrophic lateral sclerosis (ALS)source ↗
▲Full ResultsPrimeCClinical Data
PARADIGM Phase 2b trial results published in JAMA Neurology
amyotrophic lateral sclerosis (ALS)source ↗
▲IND ClearancePrimeCIND
FDA clearance to proceed with Phase 3 trial of PrimeC
amyotrophic lateral sclerosis (ALS)source ↗
▲Oral PresentationPrimeCPresentation
Long-term survival data from PARADIGM trial presented at MDA Clinical & Scientific Conference
amyotrophic lateral sclerosis (ALS)source ↗
▲Full ResultsPrimeCClinical Data
Long-term survival data from PARADIGM trial reported
amyotrophic lateral sclerosis (ALS)source ↗
▲PublicationPrimeCPresentation
PARADIGM results published in JAMA Neurology
amyotrophic lateral sclerosis (ALS)source ↗
▲Full ResultsPrimeCClinical Data
Additional long-term survival data from PARADIGM Phase 2b trial showing 65% reduction in risk of death and >14-month median survival benefit
amyotrophic lateral sclerosis (ALS)source ↗
▲Patent GrantedPrimeCIP / Competition
Australian Patent No. 2022370513 granted for PrimeC composition
ALS, Alzheimer's disease, other neurodegenerative indicationssource ↗
▲Long Term DataPrimeCClinical Data
Long-term follow-up showed 65% reduction in risk of death and median survival of 36.3 months vs 21.4 months
amyotrophic lateral sclerosis (ALS)source ↗
▲Patent GrantedPrimeCIP / Competition
U.S. Patent No. 12,527,768 granted for PrimeC combination in Alzheimer's disease
Alzheimer's diseasesource ↗
●Trial CompletionPrimeCTrial
Proof-of-concept Alzheimer's disease study (RoAD) concluded
Alzheimer's diseasesource ↗
▲AdCom ScheduledAdvisory Committee
World-renowned Alzheimer's disease expert Prof. Steven E. Arnold joins Scientific Advisory Board
▲Topline ReadoutPrimeCClinical Data
Top-line results from proof-of-concept Alzheimer's disease study (RoAD) recently concluded
Alzheimer's diseasesource ↗
▲Topline ReadoutPrimeCClinical Data
Statistically significant survival data from Phase 2b study
ALSsource ↗
▲Patent GrantedPrimeCIP / Competition
PrimeC composition patent protection expanded through 2042 with grants in Australia, Brazil, Japan and South Korea
◆Full ResultsPrimeCClinical Data
Clinical and biomarker outcomes from RoAD study expected
Alzheimer's diseasesource ↗
◆Other Regulator MilestonePrimeCEx-US Regulatory
Regulatory decision from Health Canada on NOC/c submission
ALSsource ↗
▲Safety Data UpdatePrimeCClinical Data
Safety analysis completed for PrimeC in Alzheimer's Phase 2 study; favorable tolerability profile
Alzheimer's diseasesource ↗
◆Oral PresentationPrimeCPresentation
Investor webinar to provide PARAGON trial design and timelines
amyotrophic lateral sclerosis (ALS)source ↗
◆Trial InitiationPrimeCTrial
Preparation for pivotal Phase 3 trial of PrimeC in ALS
amyotrophic lateral sclerosis (ALS)source ↗
Past FDA Catalysts and PDUFA Decisions
How NRSN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | PrimeC (extended-release formulation) | Phase 2b topline data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 84%
Micro Cap(rank 553 of 658)
Percentile Rank
NeuroSense Therapeutics Ltd. faces pipeline headwinds (25/100), with $68M risk-adjusted pipeline value, led by PrimeC in Pharmacokinetics (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PrimeC Small moleculeCompletedNCT05357950 | Amyotrophic Lateral Sclerosis | Phase 2 | COMPLETED | 69 | Nov 4, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every NRSN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ben-Noon AlonOfficer (Chief Executive Officer) | Buy | 250,000 4,534,233 held | $0.80 | 06/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NRSN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.1 % | 397.00 K | 100.00 K |
NRSN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NRSN ranks across every disease it competes in
Competitive Position is a premium feature
See how NRSN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNRSN News
NRSNNeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense Therapeutics has regained compliance with Nasdaq's minimum bid price requirement but is appealing a determination regarding its market value. The company plans to present its compliance plan to a Nasdaq Hearings Panel. Meanwhile, it continues to advance its ALS treatment, PrimeC, with promising Phase 2b study results and FDA clearance for a Phase 3 trial.
Read more →NRSN▼ -9.7%on this news· ran to -28% by day 3
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
NeuroSense Therapeutics will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026. CFO Or Eisenberg will engage in discussions about the company's lead drug candidate, PrimeC, and its recent clinical advancements in treating ALS. The company has received FDA clearance for its Phase 3 PARAGON trial, indicating progress toward regulatory approval.
Read more →NRSN▼ -26.6%on this news· ran to -42% by day 3shared move
NeuroSense Provides Business Update and Progress for the First Half of 2026
NeuroSense Therapeutics provided a business update, highlighting progress on its investigational therapy PrimeC for ALS. The company is preparing for a New Drug Submission in Canada by December 2026 and has reported promising clinical results, including a significant reduction in mortality risk. However, it also faces financial losses and uncertainties in its development strategy.
Read more →NRSN▼ -17.2%on this news
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
NeuroSense Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will focus on the clinical progress of PrimeC, its lead drug candidate for ALS, and preparations for the upcoming Phase 3 PARAGON trial. Management will also be available for one-on-one investor meetings during the event.
Read more →NRSNNeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
NeuroSense Therapeutics has announced a new strategy for advancing its ALS treatment, PrimeC, which aims to expedite regulatory approval while reducing costs. The plan includes AI-enabled formulation characterization, a comparative trial against edaravone, and a streamlined Phase 3 study. The company has already received FDA clearance to initiate the pivotal trial and is also pursuing a parallel regulatory pathway in Canada.
Read more →NRSNNeuroSense Issues CEO Letter to Shareholders
NeuroSense Therapeutics' CEO, Alon Ben-Noon, updates shareholders on the company's progress towards initiating the Phase 3 PARAGON study for PrimeC in ALS. The FDA has approved the study, which aims to enroll around 300 participants. While the company is focused on securing necessary financing, it is also exploring regulatory opportunities in Canada to expedite PrimeC's availability. The CEO and CFO have personally invested in the company, reflecting their commitment to its success.
Read more →NRSN▼ -6.9%on this news
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Therapeutics has completed the Pre-New Drug Submission process with Health Canada and is targeting a December 2026 filing for its ALS treatment, PrimeC. The company received positive feedback regarding the submission's content and structure, indicating no concerns with the proposed timeline. The NDS will be supported by evidence from the Phase 2b PARADIGM clinical program, highlighting the need for additional ALS therapies in Canada.
Read more →NRSN▼ -7.1%on this news
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
NeuroSense Therapeutics announced its intention to file a New Drug Submission for PrimeC to treat ALS, following a positive Pre-NDS meeting with Health Canada. The submission is backed by promising data from the Phase 2b PARADIGM study, which demonstrated significant long-term survival benefits. The company aims to strengthen its submission package further as it collaborates with Health Canada.
Read more →NRSNNeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
NeuroSense Therapeutics will participate in a KOL webinar hosted by Roth Capital Partners to discuss ALS treatment advancements. The webinar will feature experts addressing unmet needs in ALS, trial design, and the company's PrimeC therapy. NeuroSense's PrimeC has shown promising results in previous studies and aims for FDA accelerated approval in its upcoming Phase 3 trial.
Read more →NRSN▼ -6.3%on this news
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in ALS met its primary endpoint, showing a significant reduction in TDP-43 levels. This marks the first successful demonstration of treatment-related TDP-43 reduction in ALS patients. The study also reported a meaningful survival benefit and favorable safety profile, supporting PrimeC's potential as a disease-modifying therapy.
Read more →NRSNNeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
NeuroSense Therapeutics announced positive biomarker findings from its Phase 2 RoAD study of PrimeC in Alzheimer's disease. The study showed significant changes in key biomarkers associated with neurodegeneration, supporting PrimeC's multi-target approach. While the results are promising, the small sample size necessitates further research to validate these findings.
Read more →NRSNEverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
NeuroSense Therapeutics will participate in a community event hosted by EverythingALS to discuss emerging data on PrimeC, its lead drug candidate for ALS. The event will feature Prof. Jeffrey Rosenfeld and CEO Alon Ben-Noon, focusing on the latest developments in ALS research. NeuroSense has recently received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC.
Read more →NRSNNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
NeuroSense Therapeutics has been granted a South Korean patent for PrimeC, its lead drug candidate aimed at treating amyotrophic lateral sclerosis (ALS). The patent, which covers the formulation, manufacturing process, and pharmacokinetic characteristics of PrimeC, provides protection through 2042. This milestone is significant as it expands NeuroSense's global intellectual property offerings and supports the development and commercialization of PrimeC, which has shown promising results in earlier studies. The company is preparing for a pivotal Phase 3 trial following successful outcomes in prior stages, signaling potential advances in ALS treatment.
Read more →NRSNNeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
NeuroSense Therapeutics has received a Japanese patent for its lead drug candidate, PrimeC, which targets amyotrophic lateral sclerosis (ALS). The patent, effective until 2042, covers the unique formulation and manufacturing process. This development supports the company's strategy as it prepares for a pivotal Phase 3 clinical trial following positive results from earlier studies. The patent enhances NeuroSense's global intellectual property portfolio.
Read more →NRSN▲ +7.8%on this news· ran to +19% by day 3
NeuroSense Announces Pricing of Insider-Led PIPE Financing
NeuroSense Therapeutics has announced a PIPE financing agreement to raise $600,000 through the sale of 750,000 ordinary shares at $0.80 each. The financing is led by CEO Alon Ben-Noon and CFO Or Eisenberg, with participation from a significant existing shareholder. The funds will be used for general corporate purposes ahead of clinical milestones.
Read more →NRSN▼ -8.2%on this news
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Therapeutics has been granted a Brazilian patent for its PrimeC composition, which combines ciprofloxacin and celecoxib. This patent, valid until October 2042, strengthens the company's global intellectual property portfolio. The announcement follows positive results from a Phase 2b trial, with plans for a Phase 3 pivotal trial for ALS underway.
Read more →NRSN▼ -8.2%on this newsshared move
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics has received notifications from Nasdaq regarding non-compliance with listing requirements due to its stock price and market value falling below the necessary thresholds. The company has a compliance period until September 29, 2026, to rectify these issues. Despite the notifications, trading of its securities will continue on Nasdaq.
Read more →NRSNNeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
NeuroSense Therapeutics reported its 2025 financial results, highlighting significant progress in its PrimeC program, which has advanced to late-stage clinical development. The company demonstrated promising survival data from its Phase 2b study and received FDA clearance for a Phase 3 trial in ALS. Despite financial challenges, NeuroSense's advancements position it favorably within the neurodegenerative disease treatment landscape.
Read more →NRSNNeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
NeuroSense Therapeutics has announced key regulatory updates for its lead drug candidate, PrimeC, including a rescheduled pre-NDS meeting with Health Canada to incorporate new data. The company expects to release results from its Alzheimer's study soon and has received FDA clearance for a pivotal Phase 3 trial in ALS. These developments position NeuroSense for significant milestones in 2026.
Read more →NRSN▼ -5.4%on this news
/C O R R E C T I O N -- NeuroSense/
NeuroSense Therapeutics announced that Dr. Christian Lunetta will present new findings on their investigational therapy PrimeC for ALS at the upcoming AD/PD 2026 Conference. The presentation will highlight key clinical insights from the Phase 2b PARADIGM trial, informing the design of the global Phase 3 PARAGON trial. NeuroSense aims to provide effective treatments for ALS, which poses significant unmet medical needs. Additionally, the company is actively engaging with regulatory authorities to facilitate PrimeC's path towards potential marketing authorization.
Read more →About NeuroSense Therapeutics Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next NRSN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime